| Acceleration of clear cell renal cell carcinoma growth in mice following ... - UroToday |
|
|
UroToday The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free survival of patients with metastatic RCC, the effect on overall survival is poor. |